

Prof. UMUT KEFELİ

Personal Information

Email: umut.kefeli@kocaeli.edu.tr

Education Information

Post Doctorate of Medicine, Diğer(Kurumlar,Hastaneler Vb.), Hastaneler, İstanbul Kartal Dr.Lütfi Kırdar Eğitim Ve Araştırma Hastanesi, Turkey 2009 - 2012

Expertise In Medicine, Marmara Üniversitesi, Tıp Fakültesi, Turkey 2003 - 2008

Foreign Languages

English, B2 Upper Intermediate

Research Areas

Medicine, Internal Medicine Sciences, Internal Diseases , Oncology

Academic Titles / Tasks

Professor, Kocaeli University, Tıp Fakültesi, Dahili Tıp Bilimleri, 2019 - Continues

Associate Professor, Kocaeli University, Tıp Fakültesi, 2016 - 2019

Assistant Professor, Kocaeli Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2014 - 2016

Courses

ÜRİNER SİSTEM TÜMÖRLERİ, Under Graduate, 2016 - 2017

BAŞ ve BOYUN KANSERLERİ, Under Graduate, 2016 - 2017

KEMOTERAPİ İLAÇLARI, Under Graduate, 2016 - 2017

Articles Published in Journals That Entered SCI, SSCI and AHCI Indexes

- I. **Follicular lymphoma in a patient with splenosis: a case report**
Kefeli U., Mehtap O., Cakir Ö., Erucar A., İsgoren S., Ucuncu K.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019 (Journal Indexed in SCI)
- II. **Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection.**
Aydin D., Sendur M., Kefeli U., Unal O., Tastekin D., Akyol M., Tanrikulu E., Ciltas A., Ustaalioglu B., Uysal M., et al.
Clinical colorectal cancer, vol.16, pp.220-227, 2017 (Journal Indexed in SCI)
- III. **Netrin-1 in cancer: Potential biomarker and therapeutic target?**
Kefeli U., Ucuncu K., Cabuk D., Isik U., Sonkaya A., Acikgoz O., Ozden E., Uygun K.
TUMOR BIOLOGY, vol.39, no.4, 2017 (Journal Indexed in SCI)

- IV. **Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma.**
Aydin D., Sendur M., Kefeli U., Ustaalioglu B., Aydin O., Yildirim E., Isik D., Ozcelik M., Surmeli H., Oyman A., et al.
Clinical colorectal cancer, vol.16, pp.78-83, 2017 (Journal Indexed in SCI)
- V. **The value of plasma netrin-1 in non-small cell lung cancer patients as diagnostic and prognostic biomarker.**
Yildirim M., Kefeli U., Aydın D., Sener N., Gümüş M.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, vol.37, pp.11903-11907, 2016 (Journal Indexed in SCI)
- VI. **Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology).**
Süner A., Aydın D., Hacıoğlu M., Doğu G., İmamoğlu G., Menekşe S., Pilancı K., Yazıcı Ö., Koca D., Karaağaç M., et al.
European review for medical and pharmacological sciences, vol.20, pp.1238-43, 2016 (Journal Indexed in SCI)
- VII. **Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO).**
Aydin D., Sendur M., Kefeli U., Umut U., Tastekin D., Akyol M., Tanrikulu E., Ciltas A., Bala U., Sener D., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.21, pp.1242-1249, 2016 (Journal Indexed in SCI)
- VIII. **Efficacy and Toxicity of Cisplatin and Capecitabine Combination in the First-Line Treatment of Patients with Advanced Gastric Cancer: A Multicenter Study by the Anatolian Society of Medical Oncology**
Ciltas A., Buyukberber S., Topcu T. O. , Kucukoner M., Uyeturk U., Cihan S., Sendur M. A. , Budakoglu B., Kefeli U., Yildiz R., et al.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.2, pp.96-102, 2016 (Journal Indexed in SCI)
- IX. **Colorectal stenting for palliation and as a bridge to surgery: A 5-year follow-up study.**
Bayraktar B., Ozemir I., Kefeli U., Demiral G., Sagiroğlu J., Bayraktar O., Adali G., Ozcelik A., Tortum O.
World journal of gastroenterology, vol.21, pp.9373-9, 2015 (Journal Indexed in SCI)
- X. **Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy.**
Aydin D., Bilici A., Yavuzer D., Kefeli U., Tan A., Ercelep O., Mert A., Yuksel S., Ozcelik M., Isik D., et al.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol.17, pp.604-11, 2015 (Journal Indexed in SCI)
- XI. **Clinical importance of discordance of hormone receptors and Her2/neu status after neoadjuvant chemotherapy in breast cancer.**
Basak O., Aker V., Bilici A., Gurleyik G., Erkol B., Kefeli U., Aliustaoglu M.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.19, pp.879-86, 2014 (Journal Indexed in SCI)
- XII. **Non-small cell lung cancer in women: A distinct entity?**
Kefeli U., Oven Ustaalioglu B. B. , Yilmaz B., Aydin D., Sener N., Aliustaoglu M., Gumus M.
Gazi Medical Journal, vol.25, no.3, pp.92-96, 2014 (Journal Indexed in SCI Expanded)
- XIII. **Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience.**
Kefeli U., Benekli M., Sevinc A., Yildiz R., Kaplan M., Ciltas A., Balakan O., Isikdogan A., Coskun U., Dane F., et al.
Oncology letters, vol.6, pp.605-611, 2013 (Journal Indexed in SCI)
- XIV. **Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis.**
Korkmaz T., Seber S., Kefeli U., Sari E., Canhoroz M., Oven B., Yildirim E., Yasar N., Aydin D., Balvan O., et al.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, vol.15, pp.535-40, 2013 (Journal Indexed in SCI)
- XV. **Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience.**
Kefeli U., Buyuberber S., Akyol M., Yildiz R., Kaplan M., Ciltas A., Sevinc A., Karaca H., Seker M., Ozdemir N., et al.

Hepato-gastroenterology, vol.60, pp.647-52, 2013 (Journal Indexed in SCI)

- XVI. **The importance of multifocal/multicentric tumor on the disease-free survival of breast cancer patients: single center experience.**
Ustaalioglu B., Bilici A., Kefeli U., Şeker M., Oncel M., Gezen C., Gumus M., Demirelli F.
American journal of clinical oncology, vol.35, pp.580-6, 2012 (Journal Indexed in SCI)
- XVII. **Netrin-1 concentrations in patients with advanced gastric cancer and its relation with treatment.**
Kefeli U., Yildirim M., Aydin D., Madenci O., Yasar N., Sener N., Mert A., Yuksel S., Ercelep O., Korkmaz T., et al.
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, vol.17, pp.663-7, 2012 (Journal Indexed in SCI Expanded)
- XVIII. **Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer.**
Eser M., Kement M., Balin S., Coskun C., Kefeli U., Gumus M., Altuntas Y., Kurt N., Mayadagli A.
World journal of surgical oncology, vol.10, pp.180, 2012 (Journal Indexed in SCI)
- XIX. **The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis**
Bozcuk H., Abali H., Coskun S., Aydiner A., Çinkaya A., Demirkazik A., Özet A., Yolcu A., Balkan A., Çavdar A., et al.
World Journal of Surgical Oncology, vol.10, 2012 (Journal Indexed in SCI)
- XX. **Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.**
Kaya A., Coskun U., Ozkan M., Sevinc A., Yilmaz A., Gumus M., Unal O., Ozdemir N., Alici S., Berk V., et al.
Onkologie, vol.35, pp.576-80, 2012 (Journal Indexed in SCI)
- XXI. **Evaluation of Hodgkin lymphoma cases and determination of prognostic factors Hodgkin lenfoma olgulari{dotless}ni{dotless}n retrospektif değerlendirilmesi ve prognostik faktörlerin saptanmasi{dotless}**
Şeker M., Meng A., Bilici A., Ustaalioglu B. B. , Kefeli U., Özşeker N. I. , Mayadağlı A., Salepci T., Gümüş M.
Turk Onkoloji Dergisi, vol.26, no.3, pp.108-114, 2011 (Journal Indexed in SCI Expanded)
- XXII. **Prognostic factors in elderly patients with non-small cell lung cancer: a two-center experience**
Kefeli U., Kaya S., Ustaalioglu B., Bilici A., Kefeli A., Yildirim M., Seker M., Yilmaz B., Salepci T., Uygun K., et al.
MEDICAL ONCOLOGY, vol.28, no.3, pp.661-666, 2011 (Journal Indexed in SCI)
- XXIII. **Tissue and serum adiponectin levels in patients with gastric cancer: are there any correlations between adiponectin levels and histopathological variables?**
Seker M., Bilici A., Guler D., Ustaalioglu B., Gozu H., Erkal F., Sonmez B., Karaduman M., Kefeli U., Yildirim E., et al.
Hepato-gastroenterology, vol.58, pp.1841-6, 2011 (Journal Indexed in SCI)
- XXIV. **F-18 FDG PET/CT imaging and bronchoscopic image of tracheal recurrence in patient with non-small-cell lung cancer.**
Oven U., Kefeli U., Bilici A., Ustaalioglu R., Seker M., Cinaral F., Dogusoy I.
Clinical nuclear medicine, vol.36, pp.367-9, 2011 (Journal Indexed in SCI)
- XXV. **A retrospective analysis of women's chances to become pregnant after completion of chemotherapy: a single center experience.**
Oven U., Bilici A., Kefeli U., Seker M., Salepci T., Unal O., Gumus M.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.16, pp.349-52, 2011 (Journal Indexed in SCI)
- XXVI. **The role of PET-CT in the differential diagnosis of thymic mass after treatment of patients with lymphoma.**
Ustaalioglu B., Seker M., Bilici A., Canpolat N., Yildirim E., Kefeli U., Ustaalioglu R., Yilmaz B., Salepci T., Ozdemir N., et al.
Medical oncology (Northwood, London, England), vol.28, pp.258-64, 2011 (Journal Indexed in SCI)
- XXVII. **A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy**
Kefeli U., Bilici A., Ustaalioglu B., Kefeli A., Yildirim M., Seker M., Gumus M.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, vol.283, no.2, pp.405-407, 2011 (Journal Indexed in SCI)
- XXVIII. **The role of ¹⁸F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial**

- surgical resection: can the results of FDG PET/CT influence patients' treatment decision making?**
 Bilici A, Ustaalioglu B, Seker M, Kefeli U, Canpolat N, Tekinsoy B, Ozugur S, Gumus M.
 European journal of nuclear medicine and molecular imaging, vol.38, pp.64-73, 2011 (Journal Indexed in SCI)
- XXIX. **Pulmonary toxicity in patients receiving docetaxel chemotherapy**
 Yumuk P, Kefeli U, Ceyhan B, Dane F, Eroglu B, Gumus M, Cabuk D, Basaran G, Abacioglu U, Turhal N.
 MEDICAL ONCOLOGY, vol.27, no.4, pp.1381-1388, 2010 (Journal Indexed in SCI)
- XXX. **Prognostic significance of perineural invasion in patients with gastric cancer who underwent curative resection.**
 Bilici A, Seker M, Ustaalioglu B, Kefeli U, Yildirim E, Yavuzer D, Aydin F, Salepci T, Oncel M, Gumus M.
 Annals of surgical oncology, vol.17, pp.2037-44, 2010 (Journal Indexed in SCI)
- XXXI. **Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma.**
 Seker M, Ustaalioglu B, Bilici A, Yildirim M, Kefeli U, Barisik N, Tamer I, Gumus M.
 Leukemia research, vol.34, 2010 (Journal Indexed in SCI)
- XXXII. **Is there a cut-off value for standardized uptake values in positron emission tomography for predicting response to treatment and survival in patients with advanced non-small cell lung cancer? Single center experience.**
 Oven U, Gumus M, Bilici A, Seker M, Ustaalioglu R, Kefeli U, Salepci T, Canpolat N, Mayadagli A, Dogusoy I.
 Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.15, pp.529-36, 2010 (Journal Indexed in SCI)
- XXXIII. **Is metastatic lymph node ratio superior to the number of metastatic lymph nodes to assess outcome and survival of gastric cancer?**
 Bilici A, Ustaalioglu B, Gumus M, Seker M, Yilmaz B, Kefeli U, Yildirim E, Sonmez B, Salepci T, Kement M., et al.
 Onkologie, vol.33, pp.101-5, 2010 (Journal Indexed in SCI)
- XXXIV. **Does the metastatic lymph node ratio influence the disease-free survival of patients with breast cancer: single-center experiences.**
 Oven U, Bilici A, Kefeli U, Seker M, Yildirim E, Salepci T, Oncel M, Kement M, Gumus M.
 Oncology, vol.79, pp.105-11, 2010 (Journal Indexed in SCI)
- XXXV. **Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer.**
 Kefeli U, Dane F, Yumuk P, Karamanoglu A, Iyikesici S, Basaran G, Turhal N.
 European journal of cancer care, vol.18, pp.191-4, 2009 (Journal Indexed in SCI)

Articles Published in Other Journals

- I. **RELATIONSHIPS OF BODY MASS INDEX WITH PROGNOSTIC FACTORS AND SURVIVAL IN ENDOMETRIAL CANCER**
 YENİHAYAT E. M. , KEFELİ U., ÇABUK D., IŞIK U., ÖZDEN E., çakmak y., UYGUN K.
 Acta medica nicomedia, vol.3, no.3, pp.94-99, 2020 (Other Refereed National Journals)
- II. **Adjuvant Chemotherapy in Elderly Patients with Early-stage Non-small Cell Lung Cancer**
 KEFELİ U., Kaymaz S., Aydin D., Isik D., ÇABUK D., Sonkaya A., Acikgoz O., IŞIK U., ÖZDEN E., UYGUN K.
 BEZMIALEM SCIENCE, vol.7, no.4, pp.265-270, 2019 (Journal Indexed in ESCI)
- III. **Prognostic Factors for Operated Gallbladder Cancer.**
 Oven U, Bilici A, Seker M, Kefeli U, Aydin D., Celik S., Demir T., Erkol B.
 Journal of gastrointestinal cancer, vol.50, pp.451-457, 2019 (Journal Indexed in ESCI)
- IV. **Akciğer kanserinde sağkalımı etkileyen klinikopatolojik özellikler**
 KEFELİ U., USTAALIOĞLU B. B. , YILDIRIM M. E. , ERKOL B., AYDIN D., ŞENER N., SONKAYA A., AÇIKGÖZ Ö.
 mARMARA mEDİCAL JOURNAL, vol.28, no.1, pp.21-26, 2015 (Other Refereed National Journals)
- V. **Clinicopathological factors related to survival in lung cancer**
 KEFELİ U., Oven Ustaalioglu B. B. , Yildirim M. E. , Erkol B., Aydin D., Sener N., Sonkaya A., Acikgoz O.

MARMARA MEDICAL JOURNAL, vol.28, no.1, pp.21-26, 2015 (Journal Indexed in ESCI)

VI. İnflamatuvar Meme Kanseri Serimiz Tek Merkez Deneyimi

Ustaalioglu B. B. , BİLİCİ A., ŞEKER M., Salepçi T., Yıldırım E., KEFELİ U., Kement M., GÜMÜŞ M.
Acta Oncologica Turcica, vol.42, no.3, pp.93-99, 2009 (Other Refereed National Journals)

VII. NADİR BİR NAZOLAKRİMAL HEMANJİYOPERİSTOM OLGUSU

Ustaalioglu B. B. , ŞEKER M., BİLİCİ A., Erkol B., KEFELİ U., Yıldırım E., SÖNMEZ B., GÜMÜŞ M., Salepçi T.
Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi, vol.19, no.2, pp.93-96, 2008 (Other Refereed National Journals)

Refereed Congress / Symposium Publications in Proceedings

- I. **Perioperative FLOT: Tolerability, pathological response rates, and the role of adjuvant phase**
Ozden E., Isik U., Cakmak Y., Uslu H., Tosun M., Sahin E., Kaypak M., Cabuk D., Kefeli U., Uygun K.
ESMO 22nd World Congress on Gastrointestinal Cancer, ELECTR NETWORK, 1 - 04 July 2020, vol.31
- II. **The effect of chemotherapy on survival applied in the last term of life in cancer patients**
IŞIK U., Erol A., Cakmak Y., ÖZDEN E., KEFELİ U., ÇABUK D., UYGUN K., Simsek M.
10th Eurasian Hematology Oncology Congress, İstanbul, Turkey, 8 - 11 October 2019, vol.85
- III. **Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.**
Isik U., Kostek O., Demiray G., Dirican A., Simsek M., Buyuksimsek M., Ucar G., Gunaydin U. M. , Sakalar T., Aliyev A., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- IV. **Erken evre Seminom'xxda Radyoterap mi, Kemoterapi mi?**
KEFELİ U.
2. Ulusal Ürogenital Kanseler Kongresi, Turkey, 11 - 14 October 2018
- V. **Metastatik Renal Hücreli Karsinom Tek Merkez Deneyimi**
IŞIK U., ÖZDEN E., KEFELİ U., ÇABUK D., UYGUN K.
2. Ulusal Ürogenital Kanseler Kongresi, Turkey, 11 - 14 October 2018
- VI. **PRİMER İNCE BARSAK MALİGN MELANOM OLGUSU**
IŞIK U., ÖZDEN E., KEFELİ U., ÇABUK D., UYGUN K.
7. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Turkey, 21 - 25 March 2018
- VII. **J Gastrointest Cancer The prognostic factors for operated gallbladder cancer**
ÖVEN B. B. , ŞEKER M., KEFELİ U., aydın d.
ESMO World Congress on Gastrointestinal Cancer 2017, 28 June - 01 July 2017
- VIII. **Meme kanseri hastalarının klinik ve patolojik özelliklerinin retrospektif değerlendirilmesi ve sağkalım analizleri**
ÇABUK D., geçgel f., SONKAYA A., açığıöz ö., KEFELİ U., UYGUN K.
6. Türk Tıbbi Onkoloji Kongresi, Turkey, 23 March 2016
- IX. **Kliniğimizdeki mide kanserli hastaların klinik ve patolojik özelliklerinin retrospektif değerlendirilmesi**
ÇABUK D., kaymaz s., KEFELİ U., SONKAYA A., UYGUN K.
6. Türk Tıbbi Onkoloji Kongresi, Turkey, 23 March 2016
- X. **Akciğer kanseri olgularının klinik patolojik ve moleküler özellikleri ve sağkalım ilişkisi**
ÇABUK D., düNDAR e., SONKAYA A., KEFELİ U., UYGUN K.
6. Türk Tıbbi Onkoloji Kongresi, Turkey, 23 March 2016
- XI. **NÜKS BAZAL HÜCRE KANSERLİ BİR HASTADA VİSMODEGİB TEDAVİSİ İLE TAM CEVABIN PET BT İLE GÖSTERİLMESİ OLGU SUNUMU**
Kefeli Üçüncü A., KEFELİ U.
12. Ulusal Tıbbi Onkoloji Kongresi, İzmir, Turkey, 16 - 20 September 2015
- XII. **KOLOREKTAL KANSER HASTALARINDA ADJUVAN XELOX ve FOLFOX REJİMLERİNİN RETROSPEKTİF**

KARŞILAŞTIRILMASI ATOD ÇALIŞMASI

Uncu D., DANE F., Demir H., Menekşe S., Topçu Öztürk T., KEFELİ U., Pilancı Nur K., Baykara M., Ulaş A., Ustaalioglu B., et al.

12. Ulusal Tıbbi Onkoloji Kongresi, İzmir, Turkey, 16 - 20 September 2015

XIII. NÜKS BAZAL HÜCRELİ KANSERLİ BİR HASTADA VİSMODEGİB TEDAVİSİ İLE TAM CEVABIN FDG-PET/BT İLE GÖSTERİLMESİ OLGU SUNUMU

ÜÇÜNCÜ KEFELİ A., KEFELİ U.

12.ULUSAL TIBBİ ONKOLOJİ KONGRESİ, Turkey, 16 September 2015

XIV. Altmış Beş Yaş Üstü Rezektabl Küçük Hücreli Dışı Akciğer Kanseri Hastalarında Adjuvan Tedavi Analizi

KEFELİ U., Açıkgöz Ö., SONKAYA A., ÇABUK D., Temel Gül A., ÖZBAY S., YILDIZ D. K. , UYGUN K.

21. Ulusal Kanser Kongresi, Antalya, Turkey, 22 - 26 April 2015

XV. CLINICAL IMPORTANCE OF DISCORDANCE IN HORMONE RECEPTOR AND HER2/NEU STATUS AFTER NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER

Ustaalioglu B. B. O. , Vardar F. A. , Bilici A., Gurleyik G., Erkol B., Kefeli U.

39th ESMO Congress (ESMO), Madrid, Spain, 26 - 30 September 2014, vol.25

XVI. Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (MCRPC) after docetaxel chemotherapy: Multicentric experience of Anatolian Society of Medical Oncology

Demirci U., Oflazoglu U., Kodaz H., Ciltas A., Kefeli U., Akyol M., Ozturk B., Geredell C., Seker M. M. , Clhan S., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32

XVII. COMPARISON OF SECOND LINE TREATMENT OUTCOMES BETWEEN SENSITIVE AND REFRACTORY SMALL CELL LUNG CANCER PATIENTS: A RETROSPECTIVE ANALYSIS

Korkmaz T., Seber S., SARI E., Canhoroz M., Ustaalioglu B. O. , Kefeli U., Balvan O., Gumus M., Yasar N., Turhal S. N.

37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna, Austria, 28 September - 02 October 2012, vol.23, pp.497-498

XVIII. PLASMA M30 AND M65 LEVELS IN PATIENTS WITH ADVANCED GASTRIC CANCER: IS THERE AN IMPACT ON SURVIVAL OF PATIENTS?

Bilici A., Ustaalioglu B. B. O. , Orcun A., Ercan S., Seker M., Kefeli U., Yilmaz B. E. , Yildirim M. E. , Gezen C., Gumus M.

35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, Italy, 8 - 12 October 2010, vol.21, pp.48

XIX. SERUM M30 AND M65 VALUES IN PATIENTS WITH ADVANCED STAGE NON-SMALL CELL LUNG CANCER COMPARED WITH HEALTHY CONTROL GROUP

Ustaalioglu B. O. , Bilici A., Ercan S., Orcun A., Seker M., Kefeli U., Ozkan A., Yilmaz B. E. , Yildirim M. E. , Gumus M.

35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, Italy, 8 - 12 October 2010, vol.21, pp.72-73

XX. Is metastatic lymph node ratio superior to the number of metastatic lymph nodes to assess outcome and survival of gastric cancer

BİLİCİ A., USTAALIOĞLU B., GÜMÜŞ M., ŞEKER M., ERKOL B., SÖNMEZ B., YILDIRIM M. E. , KEFELİ U., SALEPÇİ T., KEMENT M.

2010 Gastrointestinal Cancers Symposium, United States Of America, 22 - 24 January 2010

XXI. THE IMPORTANCE OF LIVER METASTASECTOMY IN METASTATIC COLORECTAL CANCER PATIENTS: SINGLE CENTER EXPERIENCES

Ustaalioglu O. B. , Seker M., Bilici A., Salepci T., Kefeli U., Oncel M., Yildirim E., Yilmaz B., Kement M., Gumus M.

12th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 30 June - 03 July 2010, vol.21, pp.68

XXII. Pulmonary toxicity in patients receiving docetaxel chemotherapy

Kefeli U., YUMUK P. F. , CEYHAN B., DANE F., Eroglu B., Cabuk D., Basaran G., Teomete M., Turhal N. S.

45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27

XXIII. The prognostic impact of body mass index (BMI) in early breast cancer (BC) patients (pts).

Iyikesici M., Kefeli U., Basaran G., Dane F., Ekenel M., Yumuk P., Turhal N.

41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23

Citations

Total Citations (WOS):321

h-index (WOS):10